

## Supplementary data

### S1. Figures




Figure S1. Calibration plots in quintiles for model IV re-fitted in the complete data with A-C. Altered  $Dx\%[Gy]$  (A: D1%[Gy]; B\*: The used D5%[Gy]; C: D10%[Gy]), and D-F. Altered  $\alpha/\beta$  ratio values (D:  $\alpha/\beta=1Gy$ ; E\*: The used  $\alpha/\beta=3Gy$ ; F:  $\alpha/\beta=5Gy$ ). Note: Solid lines: Identity lines; Error bars: exact 95% binomial CIs.

## **S2. Tables**

*Table S1.* The symptom rate for the late moderate to severe ( $\geq$ Grade 2) GI and GU toxicities. \*: Analyzed symptoms.

<b>Symptom</b>	<b>Rate (N) [%]</b>
<b>GI</b>	
Colitis	1 (4)
Constipation	2 (8)
Diarrhea	1 (4)
Fecal incontinence	1 (3)
GI toxicity	19 (101)*
Hemorrhoids	1 (5)
Proctitis	14 (73)*
<b>GU</b>	
Bladder obstruction	1 (4)
Bladder spasm	<1 (2)
Cystitis	6 (29)
GU toxicity	28 (145)*
Pollakiuria	18 (92)*
Renal GU Other	5 (24)
Urethral obstruction	1 (4)
Urethral stricture	2 (12)
Urinary incontinence	4 (21)
Urinary retention	4 (23)
Urinary stenosis	<1 (1)

*Table S2.* Summary of the % of patients fulfilling each of the four rectal dose-planning constraints. *Note:*  
*All dose levels are given as (3)[EQD2Gy].*

Proportion fulfilling rectal constraints    **V59Gy[%]≤50**    **V64Gy[%]≤35**    **V69Gy[%]≤25**    **V74Gy[%]≤15**

		<b>V59Gy[%]≤50</b>	<b>V64Gy[%]≤35</b>	<b>V69Gy[%]≤25</b>	<b>V74Gy[%]≤15</b>
<b>All patients</b>					
Late GI≥2 (N=101)		0.99	0.97	0.92	0.77
No late GI≥2 (N=420)		0.99	0.97	0.96	0.86
<b>3DCRT</b>					
Late GI≥2 (N=19)		1.00	1.00	0.84	0.74
No late GI≥2 (N=89)		0.99	0.98	0.96	0.81
<b>IMRT</b>					
Late GI≥2 (N=82)		0.99	0.96	0.94	0.78
No late GI≥2 (N=331)		0.99	0.97	0.96	0.88